You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,871,790


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,871,790
Title:Anthrax bioassays and methods of treating and diagnosing anthrax infection
Abstract: Based on the observation that exposure of cells or animals to anthrax lethal toxin results in activation of the intracellular enzyme caspase-1/IL-1 converting enzyme (ICE), which, in turn, leads to production and extracellular release of the cytokine substrates of ICE: interleukin 1 beta (IL-1.beta.) and interleukin 18 (IL-18), disclosed herein are bioassays that can be used to determine the efficacy of a potential anthrax therapeutic agent and for screening test agents to identify anthrax therapeutic agents. Also disclosed herein are methods of diagnosing and treating anthrax infection.
Inventor(s): Frucht; David M. (Vienna, VA), Cordoba-Rodriguez; Ruth (Baltimore, MD)
Assignee: The United States of America as represented by the Department of Health and Human Services (Washington, DC) N/A (N/A)
Application Number:11/071,799
Patent Claims:1. A method of identifying an agent that decreases anthrax-induced activation of caspase-1/IL-1 converting enzyme (ICE), comprising: contacting a test agent with a J774A.1 cell expressing ICE, wherein the cell expressing ICE is a cell infected with Bacillus anthracis spore(s) or exposed to an anthrax toxin that induces activation of ICE; and determining whether ICE activity is decreased in the cell, wherein determining whether ICE activity is decreased comprises comparing the ICE activity to a baseline or a control, wherein a decrease in ICE activity in the cell compared to the baseline or control indicates the test agent decreases anthrax-induced activation of ICE.

2. The method of claim 1, wherein determining whether ICE activity is decreased comprises determining an amount of activated IL-1.beta. or activated IL-18 produced by the cell.

3. The method of claim 1, wherein the anthrax toxin comprises anthrax lethal toxin (LT).

4. The method of claim 1, wherein the control comprises a second cell infected with Bacillus anthracis spore(s) or exposed to an anthrax toxin and expressing ICE but not contacted with the test agent, wherein a decrease in ICE activity in the cell compared to the second cell indicates the test agent decreases anthrax-induced activation of ICE.

5. The method of claim 1, wherein the test agent comprises an antibody that recognizes anthrax LT.

6. The method of claim 2, wherein determining whether ICE activity is decreased comprises determining an amount of activated IL-1.beta. or activated IL-18 secreted by the cell.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.